- Home
- DLHC vs ADAG Comparison
DLHC vs ADAG Comparison
Compare DLHC & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- ADAG
- Stock Information
- Founded
- DLHC 1969
- ADAG 2011
- Country
- DLHC United States
- ADAG China
- Employees
- DLHC N/A
- ADAG N/A
- Industry
- DLHC Business Services
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- ADAG Health Care
- Exchange
- DLHC Nasdaq
- ADAG Nasdaq
- Market Cap
- DLHC 79.6M
- ADAG 91.4M
- IPO Year
- DLHC N/A
- ADAG 2021
- Fundamental
- Price
- DLHC $5.70
- ADAG $1.83
- Analyst Decision
- DLHC
- ADAG Strong Buy
- Analyst Count
- DLHC 0
- ADAG 1
- Target Price
- DLHC N/A
- ADAG $8.00
- AVG Volume (30 Days)
- DLHC 95.5K
- ADAG 51.3K
- Earning Date
- DLHC 07-30-2025
- ADAG 07-24-2025
- Dividend Yield
- DLHC N/A
- ADAG N/A
- EPS Growth
- DLHC 75.08
- ADAG N/A
- EPS
- DLHC 0.38
- ADAG N/A
- Revenue
- DLHC $377,074,000.00
- ADAG $103,204.00
- Revenue This Year
- DLHC N/A
- ADAG $6,488.89
- Revenue Next Year
- DLHC N/A
- ADAG $57.50
- P/E Ratio
- DLHC $15.03
- ADAG N/A
- Revenue Growth
- DLHC N/A
- ADAG N/A
- 52 Week Low
- DLHC $2.72
- ADAG $1.33
- 52 Week High
- DLHC $11.99
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- DLHC 55.57
- ADAG 51.18
- Support Level
- DLHC $5.60
- ADAG $1.74
- Resistance Level
- DLHC $5.97
- ADAG $1.98
- Average True Range (ATR)
- DLHC 0.20
- ADAG 0.12
- MACD
- DLHC -0.04
- ADAG -0.01
- Stochastic Oscillator
- DLHC 46.77
- ADAG 47.22
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.